Results 271 to 280 of about 67,015 (304)

Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy. [PDF]

Heart
Wang H, Li J, Hsi DH, Li W, Ta S, Jiao Y, Shan B, Chang L, Ou X, Yao L, Wang B, Wang J, Lei C, Liu L.   +13 more
europepmc   +1 more source

Model-Informed Recommendation of Mavacamten Posology for Chinese Adults With Obstructive Hypertrophic Cardiomyopathy. [PDF]

CPT Pharmacometrics Syst Pharmacol
Wu X, Puli S, Chen N, Tian Z, Hsu P, Sun J, Lyu C, Merali S, Zhang J.   +8 more
europepmc   +1 more source

Covert Transthyretin Amyloidosis Mimicking Advanced Obstructive Hypertrophic Cardiomyopathy Despite Multiple Negative ^99mTc-PYP Radionuclide Scans. [PDF]

JACC Case Rep
Reuter M, Wu W, Massera D, Phillips L, Zhou F, Alvarez-Cardona J, Reyentovich A, Larson D, Maleszewski J, Sherrid M.   +9 more
europepmc   +1 more source

DECIPHERING COMPLEXITY: A CASE OF MECHANICAL HEMOLYSIS IN HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY WITH CONCURRENT VITAMIN B12 DEFICIENCY

Thirumala Keerthi Chandrika Kammaripalle, Amulya Gade, Humza Rana, Paweł Borkowski, Sai Priya Kandukoori   +4 more
openalex   +1 more source

Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy. [PDF]

Biomark Res
Cui H, Wang Y, Hua X, Han J, Mo H, Liu S, Wang H, Huang S, Zhao Y, Chen X, Zhao Q, Jia H, Chang Y, Song J.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Obstructive Hypertrophic Cardiomyopathy

Progress in Cardiovascular Nursing, 2004
Hypertrophic cardiomyopathy (HCM) is a primary disease of cardiac muscle characterized by a thickening of the left ventricular wall and often predominantly affecting the interventricular septum. This paper presents a case study of a 53‐year‐old female with a dynamic and obstructive form of HCM. The study includes a case presentation, clinical findings,
Melissa A, Graham-Cryan, Gina, Rowe, Londa, Hathaway, Susan, Biddle, Dorothy, Tripodi, Lameh, Fananapazir   +5 more
openaire   +2 more sources

Differential diagnosis of hypertrophic cardiomyopathies: typical (subaortic) hypertrophic obstructive cardiomyopathy, atypical (mid-ventricular) hypertrophic obstructive cardiomyopathy and hypertrophic non-obstructive cardiomyopathy

European Heart Journal, 1983
Previous clinical studies in patients with hypertrophic cardiomyopathies predominantly comprised patients with typical subaortic HOCM and in many other studies patients with 'hypertrophic' cardiomyopathies were investigated; i.e. no distinction was made between patients with the typical obstructive, the atypical obstructive and the non-obstructive ...
H, Kuhn, J, Mercier, E, Köhler, H, Frenzel, W, Hort, F, Loogen   +5 more
openaire   +2 more sources

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.

New England Journal of Medicine
BACKGROUND One of the major determinants of exercise intolerance and limiting symptoms among patients with obstructive hypertrophic cardiomyopathy (HCM) is an elevated intracardiac pressure resulting from left ventricular outflow tract obstruction ...
M. Maron, A. Masri, M. Nassif, R. Barriales-Villa, M. Arad, Nuno Cardim, L. Choudhury, B. Claggett, C. Coats, H. Düngen, Pablo Garcia-Pavia, A. Hagège, J. Januzzi, M. Lee, Gregory D Lewis, Changsheng Ma, Michelle Michels, I. Olivotto, A. Oręziak, A. Owens, J. Spertus, Scott D. Solomon, J. Tfelt-Hansen, Marion van Sinttruije, Josef Veselka, Hugh Watkins, D. Jacoby, S. Heitner, S. Kupfer, F. Malik, L. Meng, A. Wohltman, T. Abraham   +32 more
semanticscholar   +1 more source

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.

New England Journal of Medicine
BACKGROUND Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy.
Pablo García-Pavía, M. Maron, A. Masri, B. Merkely, M. Nassif, M. L. Peña-Peña, R. Barriales-Villa, Ozlem Bilen, Melissa Burroughs, B. Claggett, J. Costabel, E. D. Correia, A. Dybro, P. Elliott, S. M. Hegde, N. Lakdawala, Gregory D Lewis, Amy Mann, Z. Miao, Ajith Nair, S. Poulsen, P. Reant, P. Schulze, Scott D. Solomon, Andrew Wang, Regina L. Sohn, Indrias Berhane, S. Heitner, D. Jacoby, S. Kupfer, F. Malik, A. Wohltman, M. Fifer   +32 more
semanticscholar   +1 more source

Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks

Circulation, 2022
Background: Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy (oHCM) is associated with variable morbidity and mortality.
M. Desai, A. Owens, J. Geske, K. Wolski, S. Saberi, Andrew Wang, M. Sherrid, P. Cremer, S. Naidu, Nicholas G. Smedira, H. Schaff, E. McErlean, Christina Sewell, A. Balasubramanyam, K. Lampl, A. Sehnert, S. Nissen   +16 more
semanticscholar   +1 more source